期刊文献+

高血压患者血浆尾加压素Ⅱ的变化 被引量:8

下载PDF
导出
摘要 目的观察高血压患者血浆尾加压素Ⅱ(U-Ⅱ)变化及其与血压的相关性,了解U-Ⅱ的可能作用和临床意义。方法选择原发性高血压患者80名,根据中国高血压防治指南的高血压分级标准将入选病例分为3组:高血压1、2、3级;采用放射免疫法检测血浆U-Ⅱ的含量;同时选择体检者20名作为正常对照组。结果高血压患者U-Ⅱ的含量高于对照组[(3.3±1.3)比对照组:(1.8±0.6)pmol/L,P<0.01]。高血压1、2、3级组U-Ⅱ的含量分别为(1.6±1.0)、(3.2±1.0)、(4.3±1.0)pmol/L,3组间差异有非常显著意义(P<0.01)。高血压分级与血浆U-Ⅱ含量的变化呈显著正相关(r=0.641,P<0.01)。结论高血压患者血浆U-Ⅱ含量高于正常对照组,与高血压分级显著相关。
出处 《中华高血压杂志》 CAS CSCD 北大核心 2007年第2期159-160,共2页 Chinese Journal of Hypertension
  • 相关文献

参考文献8

  • 1[2]Takuya Watanabe,Toshiaki Suguro,Tomoko Kanome,et al.Human urotensin Ⅱ accelerates foam cell formation in human monocyte-derived macrophages[J].Hypertens,2005,46:738-744.
  • 2[3]Totsune K,Takahashi K,Arihara Z,et al.Increased plasma urotensin-Ⅱ levels in patients with diabetes mellitus[J].Clin Sei(Lond),2003,104:1-5.
  • 3[4]Rossowski WJ,Cheng BL,Taylor JE,et al.Human urotensinⅡinduced aorta ring contractions are mediated by protein kinase C,tyrosine kinasea and Rho kinase:inhibition by somatostatin receptor agonists[J].Eur J Pharmacol,2002,438:159-170.
  • 4[5]Watanabe T,Pakala R,Katagiri T,et al.Synergistic effect of urotensin Ⅱ with serotonin on vascular smooth muscle cell prolif eration[J].J Hypertens,2001,19:2191-2196.
  • 5张勇刚,陈亚红,马春艳,齐永芬,庞永正,杨军,张肇康,唐朝枢.尾加压素Ⅱ的促丝裂作用[J].中国动脉硬化杂志,2001,9(1):14-16. 被引量:61
  • 6[7]Done Onan,Luisa Pipolo,Eunice Yang,et al.Urotensin-Ⅱ promotes hypertrophy of cardiac myocytes via mitogen-activated protein Kinases[J].Molecular Endocrinology,2004,18:2344-2354.
  • 7许丹,刘昌慧,郝亚容.尾加压素Ⅱ在心血管疾病中的研究进展[J].高血压杂志,2005,13(10):608-610. 被引量:2
  • 8[9]Bohm F,Penow J.Urotensin-Ⅱ evokes potent vasoconstriction in humans in vivol[J].Br J Pharmacol,2002,135:25-27.

二级参考文献32

  • 1张勇刚 杨军 等.尾加压素Ⅱ在心血管系统中的作用[J].北京医科大学学报,2000,32(2):133-133.
  • 2张勇刚,北京医科大学学报,2000年,32卷,2期,133页
  • 3Liu Q,Biochem Biophys Res Commun,1999年,266卷,1期,174页
  • 4Coulouarn Y,FEBS Lett,1999年,457卷,28页
  • 5Hillier C, Berry C, Petrie MC, et al. Effects of urotensin Ⅱ in human arteries and veins of varing caliber[J].Circulation,2001,103:1378-1381.
  • 6Behm DJ, Harrison SM, Ao Z, et al. Deletion of the UT receptor gene results in the selective loss of urotensin Ⅱ contractile activity in aortae isolated from UT receptor knockout mice[J].Br J Pharmacol,2003,139:464-472.
  • 7Tasaki K, Hori M, Ozaki H, et al. Mechanism of human urotensin Ⅱ induced contraction in rat aorta[J].J Pharmacol Sci,2004,94:376-383.
  • 8Wojciech J, Rossowski BL, Cheng JE, et al. Human Urotensin Ⅱ induced aorta ring contractions are mediated by protein kinase C, tyrosine kinase and Rho-kinase:inhibition by somatostatin receptor antagonists[J].Eur J Pharmcol,2002,438:159-170.
  • 9Sauzeau V, Le Mellionnec E, Bertoglio J, et al. Human urotensin Ⅱ induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase[J].Circ Res,2001,88:1102-1104.
  • 10Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin Ⅱ in human pulmonary and abdominal resistance arteries[J].Am J Physiol Heart Circ Physiol,2001,280:H925.

共引文献61

同被引文献58

引证文献8

二级引证文献45

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部